ADRENAL INCIDENTALOMA, BREAST CANCER AND UNRECOGNIZED MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
Adrenal incidentaloma
Breast cancer
Multiple endocrine neoplasia 1
Journal
Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720
Informations de publication
Date de publication:
Historique:
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
ppublish
Résumé
The incidence of adrenal incidentaloma has been increasing proportional to the use of radiologic examination. Multiple endocrine neoplasia1 (MEN1) syndrome may present with various tumors. The present study reports a case of adrenal incidentaloma with unrecognised MEN1 syndrome associated with breast cancer. A 48-year-old woman presented with a 2.4cm left adrenal incidentaloma on abdominal computed tomography. Her history revealed primary amenorrhea, recurrent peptic ulcer and nephrolithiasis. Laboratory and radiologic examination revealed two pancreatic tail mass lesions with markedly elevated gastrin levels (1462 pg/mL), hypercalcemia with increased parathyroid hormone levels (72 pg/mL), a 1.5cm pituitary mass with hyperprolactinemia (234 ng/mL), a 1.0cm meningioma and a nonfunctional left adrenal mass. During this image work up, a 0.6cm nodule in the right breast was incidentally detected. Surgeries (laparoscopic distal pancreatectomy, parathyroidectomy and wide local excision of breast) and pathologic findings confirmed pancreatic neuroendocrine tumors, parathyroid gland hyperplasia, and breast cancer. Carbergoline treatment for 12 months decreased prolactin levels to 27 ng/mL. Genetic testing using peripheral blood revealed a pathogenic variant in MEN1 on chr11q13 (NM_000244.3:c.1365+1_1365+11 del, GTGAGGGACAG, heterozygous). Considering the increasing incidence of adrenal incidentaloma and 20% prevalence of adrenal tumors in patients with MEN1, it is important to rule out MEN1 association in patients with adrenal incidentaloma. Additionally, breast cancer was detected during MEN1 work-up in this case. Female patients with MEN1 are at increased risk for breast cancer. Therefore, intensified breast cancer screening at a relatively young age should be considered in female MEN1 patients.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of adrenal incidentaloma has been increasing proportional to the use of radiologic examination. Multiple endocrine neoplasia1 (MEN1) syndrome may present with various tumors. The present study reports a case of adrenal incidentaloma with unrecognised MEN1 syndrome associated with breast cancer.
CLINICAL CASE
METHODS
A 48-year-old woman presented with a 2.4cm left adrenal incidentaloma on abdominal computed tomography. Her history revealed primary amenorrhea, recurrent peptic ulcer and nephrolithiasis. Laboratory and radiologic examination revealed two pancreatic tail mass lesions with markedly elevated gastrin levels (1462 pg/mL), hypercalcemia with increased parathyroid hormone levels (72 pg/mL), a 1.5cm pituitary mass with hyperprolactinemia (234 ng/mL), a 1.0cm meningioma and a nonfunctional left adrenal mass. During this image work up, a 0.6cm nodule in the right breast was incidentally detected. Surgeries (laparoscopic distal pancreatectomy, parathyroidectomy and wide local excision of breast) and pathologic findings confirmed pancreatic neuroendocrine tumors, parathyroid gland hyperplasia, and breast cancer. Carbergoline treatment for 12 months decreased prolactin levels to 27 ng/mL. Genetic testing using peripheral blood revealed a pathogenic variant in MEN1 on chr11q13 (NM_000244.3:c.1365+1_1365+11 del, GTGAGGGACAG, heterozygous).
CONCLUSION
CONCLUSIONS
Considering the increasing incidence of adrenal incidentaloma and 20% prevalence of adrenal tumors in patients with MEN1, it is important to rule out MEN1 association in patients with adrenal incidentaloma. Additionally, breast cancer was detected during MEN1 work-up in this case. Female patients with MEN1 are at increased risk for breast cancer. Therefore, intensified breast cancer screening at a relatively young age should be considered in female MEN1 patients.
Identifiants
pubmed: 32377250
doi: 10.4183/aeb.2019.513
pii: aeb.2019.513
pmc: PMC7200108
doi:
Types de publication
Case Reports
Langues
eng
Pagination
513-517Informations de copyright
©by Acta Endocrinologica Foundation.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Langenbecks Arch Surg. 2007 Jul;392(4):437-43
pubmed: 17235589
J Clin Endocrinol Metab. 1998 Aug;83(8):2621-6
pubmed: 9709921
Breast Cancer Res Treat. 2010 Jul;122(2):395-407
pubmed: 19847644
Eur J Endocrinol. 2012 Feb;166(2):269-79
pubmed: 22084155
Oncol Lett. 2014 Jul;8(1):230-234
pubmed: 24959251
Nat Rev Endocrinol. 2011 Jun 28;7(11):668-80
pubmed: 21709710
Clin Endocrinol (Oxf). 2015 Mar;82(3):327-229
pubmed: 25279812
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
Arch Surg. 1996 Jul;131(7):699-702
pubmed: 8678766
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2083-2090
pubmed: 28323962
N Engl J Med. 2014 Aug 7;371(6):583-4
pubmed: 25099597
Int J Endocr Oncol. 2017;4(4):167-185
pubmed: 29326808
Hum Mutat. 1999;13(3):175-85
pubmed: 10090472
Cell Rep. 2017 Mar 7;18(10):2359-2372
pubmed: 28273452
J Pathol. 2013 Mar;229(4):546-58
pubmed: 23180448